NURPF Stock UPDATES Neuren Pharmaceutica (NURPF) 0.1000 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Neuren Pharmaceutica (NURPF) 0.1000 $NURPF

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2014
M2 - Wed Jun 25, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5b6wvm/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Neuren Pharmaceuticals Limited - Paladin Labs Inc. - Protemix Corporation Limited - Relevare Pharmaceuticals Ltd. - Regenesance BV For more information visit http://www.researchandmarkets.com/research/5b6wvm/peripheral

Fragile X Syndrome - Pipeline Review, H2 2013
M2 - Thu Jan 23, 8:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/gmtj7c/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2013" report to their offering. 'Fragile X Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Scope - A snapshot of the global therapeutic scenario for Fragile X Syndrome. - A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Companies Mentioned F. Hoffmann-La Roche Ltd. Novartis AG Paratek Pharmaceuticals, Inc. Neuren Pharmaceuticals Limited Cortex Pharmaceuticals, Inc. Seaside Therapeutics, LLC Snowdon Inc. Marinus Pharmaceuticals, Inc. Nexgenix Pharmaceuticals, LLC aFraxis Inc. Alcobra Ltd Sage Therapeutics Confluence Pharmaceuticals LLC SMaRT Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/gmtj7c/fragile_x About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Dementia - Pipeline Review, H2 2012: Plan Mergers and Acquisitions Effectively By Identifying Players of the Most Promising Pipeline
M2 - Mon Jan 14, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jbsd8v/dementia) has announced the addition of Global Markets Direct's new report "Dementia - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Dementia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. Dementia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Dementia. - Coverage of products




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 278

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 81

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 69

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 64

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 98

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 99

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 276

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 139

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading

Top 5 Most Recently Viewed Articles

PHX Minerals Set to Release Full-Year 2024 Financial Results

Updated Category News Views 176

PHX Minerals Reveals Upcoming Financial Results Announcement PHX MINERALS INC., commonly known as PHX, is preparing to share its financial results for the year that concluded on December 31, 2024. This announcement is eagerly awaited by investors and stakeholders, marking a significant moment in understanding the company’s financial health and future outlook. Details of...

Continue Reading
Baird Optimistic on First Industrial Realty Trust Growth Ahead

Updated Category News Views 183

Baird's Positive Outlook for First Industrial Realty Trust Baird has reaffirmed its positive stance on First Industrial Realty Trust (NYSE: FR), maintaining an Outperform rating alongside a $61.00 price target. The firm's analysis indicates that the company's core portfolio is projected to deliver a stable 6% annual growth, signaling strong performance prospects for...

Continue Reading
Aprea Therapeutics Secures $3.1 Million Investment for Growth

Updated Category News Views 151

Aprea Therapeutics Secures $3.1 Million Investment Aprea Therapeutics, Inc. (Nasdaq: APRE), a forward-thinking clinical-stage biopharmaceutical company, has announced a notable private placement aimed at enhancing its development of innovative cancer treatments. This financing comes from a blend of new and existing investors, reflecting confidence in the company’s...

Continue Reading
Silal and SVG Forge New Paths in Sustainable Agriculture

Updated Category News Views 174

Silal and SVG Forge New Paths in Sustainable Agriculture In a significant development for the agricultural sector, Silal, a leading agri-food and technology company, and Shouguang Colorful Manor Modern Agriculture Co., Ltd (SVG) have entered a joint venture that stands to revolutionize sustainable agriculture practices. This landmark agreement was witnessed by eminent...

Continue Reading